PARNF — Parnell Pharmaceuticals Holdings Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -77.59% | ||
| Return on Equity | -97.39% | ||
| Operating Margin | -140.85% | ||
Financial Summary
| Year End 31st Dec | Unit | 2011 | 2012 | 2013 | 2014 | 2015 | 2016E | 2017E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | n/a | 6.29 | 9.54 | 7.54 | 13.17 | n/a | n/a | 27.92% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Parnell Pharmaceuticals Holdings Ltd is an Australia-based company, which is engaged in offering the global veterinary pharmaceutical business marketing products in 14 countries. The Company operates sterile manufacturing facilities and offers digital technology platforms that integrate with the Company’s products to offer veterinarians and animal owners superior solutions for their animal health needs. The Company also provides a fully integrated animal health platform. The Company’s mySYNCH is a digital tool to help veterinarians and producers optimize reproduction and maximize economic gains. The Company’s products include GONAbreed, estroPLAN, and RESPIRmycin. GONAbreed is used for the treatment of cystic ovaries and used in cattle synchronization protocols. The estroPLAN is used in animals with unobserved or non-detected estrus in cattle undergoing synchronization protocols. The RESPIRmycin is used for the treatment of respiratory disease in beef and non-lactating dairy cattle.
Directors
- Last Annual
- December 31st, 2015
- Last Interim
- June 30th, 2016
- Incorporated
- June 25th, 2009
- Public Since
- June 18th, 2014
- No. of Employees
- 51
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 18,023,814
- Address
- PO Box 1035, MASCOT, 1460
- Web
- https://parnell.com
- Phone
- +61 800665882
- Auditors
- PricewaterhouseCoopers
Upcoming Events for PARNF
Similar to PARNF
Acacia Diversified Holdings
Pink Sheets on Nasdaq
Acusphere
Pink Sheets on Nasdaq
Adorbs
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
FAQ
As of Today at 19:16 UTC, shares in Parnell Pharmaceuticals Holdings are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Parnell Pharmaceuticals Holdings last closed at $0.00 and the price had moved by -99.96% over the past 365 days. In terms of relative price strength the Parnell Pharmaceuticals Holdings share price has underperformed the S&P500 Index by -99.96% over the past year.
There is no consensus recommendation for this security.
Parnell Pharmaceuticals Holdings does not currently pay a dividend.
Parnell Pharmaceuticals Holdings does not currently pay a dividend.
Parnell Pharmaceuticals Holdings does not currently pay a dividend.
To buy shares in Parnell Pharmaceuticals Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Parnell Pharmaceuticals Holdings had a market capitalisation of .
Here are the trading details for Parnell Pharmaceuticals Holdings:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: PARNF
Based on an overall assessment of its quality, value and momentum Parnell Pharmaceuticals Holdings is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Parnell Pharmaceuticals Holdings. Over the past six months, its share price has underperformed the S&P500 Index by -99.72%.
As of the last closing price of $0.00, shares in Parnell Pharmaceuticals Holdings were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Parnell Pharmaceuticals Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Parnell Pharmaceuticals Holdings' management team is headed by:
- Alan Bell - NEC
- Robert Joseph - PRE
- Brad Mccarthy - CFO
- Anthony Hartnell - IND